Dimethyl sulfoxide toxicity in umbilical cord blood transplantation in patients less than 4.5 kilos of weigh by Mancías Guerra, Consuelo et al.
ARTICLE IN PRESS
hematol transfus cell ther. 2021;xxx(xx):1−4
Hematology, Transfusion and Cell Therapy
www.htc t .com.brCase ReportDimethyl sulfoxide toxicity in umbilical cord blood
transplantation in patients less than 4.5 kilos of weighConsuelo Mancías-Guerra, MD a,*, Sandra Abigail Sanchez-García b,
Sofía Alejandra Carre~no-Salcedo a, Cesar Homero Gutierrez-Aguirre, MDa
aUniversidad Autonoma de Nuevo Leon, Servicio de Hematología del Hospital Universitario “Dr. Jose Eleuterio Gonzalez”,
Monterrey, Nuevo Leon, Mexico
bUniversidad Autonoma de Nuevo Leon, Facultad de Medicina y Hospital Universitario “Dr. Jose Eleuterio Gonzalez”,
Monterrey, Nuevo Leon, MexicoA R T I C L E I N F O
Article history:
Received 10 August 2020
Accepted 14 April 2021
Available online xxxIntroduction
In primary immunodeficiencies, including severe combined
immunodeficiency (SCID), the only potentially curative ther-
apy is allogeneic hematopoietic stem cell transplantation
(HSCT), which should be performed as soon as possible. There
are several sources of hematopoietic stem cells, including
bone marrow, peripheral blood stem cells (PBSC) and umbili-
cal cord blood.
On the other hand, dimethyl sulfoxide (DMSO) is the most
used cryoprotectant for hematopoietic progenitors cell stor-
age; nevertheless this molecule is related to several adverse
events (AEs) at the time of its infusion. Although there is no
cutoff point in patient weight that determines an increased* Corresponding author at: Universidad Autonoma de Nuevo Leon,
Hospital Universitario “Dr. Jose E. Gonzalez”, Servicio de Hemato-
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is a relationship between a lower volume of DMSO per kilo of
weight infused with a higher probability of an uneventful
stem cell infusion.
We report three successful cases of umbilical cord blood
transplantation (UCBT) after a reduce intensity conditioning
(RIC) regimen in infants with 4.5 kilos of weight or less with
SCID, without side effects due to DMSO. In these three
patients, the risk of toxicity was important because of their
low weight.Case report
Case 1
A two-month old, 2.4 kg Hispanic female (Table 1) with SCID
was treated with intravenous gamma globulin once per week.
She was transplanted with a 4/6 mismatch Hispanic cord
blood unit (CBU) using a RIC regimen consisting of fludarabine
40 mg/m2/day for three days, cyclophosphamide 350 mg/m2/
day for three days and a single dose of melphalan 140 mg/m2.ociação Brasileira de Hematologia, Hemoterapia e Terapia Celular.
eativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1 – Demographic data.





1 2 F 2.4 17 7 None Alive
2 4 F 3.7 47 12.7 Irritability Alive
3 9 M 4.3 18 4.18 None Alive
Table 2 – Total nucleated cells (TNC) data.






1 35.48 £ 107/kg 29.1 £ 107/kg 82%
2 26.85 £ 107/kg 21.48 £ 107/kg 80%
3 24.7 £ 107/kg 20.3 £ 107/kg 82%
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phylaxis. Intravenous clorphenamine 0.2 mg/kg, ondansetron
0.2 mg/kg, and hyperhydration were used to prevent DMSO
toxicity. The CBU was infused immediately after thawing and
washing DMSO with Rubinstein’s method without any modi-
fication of the process, with no side effects during infusion.
She received 29.1 £ 107/kg of total nucleated cells (TNC)
(Table 2) and 8.6 £ 105/kg of CD34+ cells (Table 3). She
engrafted >0.5 £ 109/L neutrophils on day +15, and >20 £ 109/
L platelets on day +19. Forty-one months after transplanta-
tion, full engraftment was achieved, and the patient was free
of infections andmedications.
Case 2
A 4-month old Hispanic 3.7 kg female (Table 1) with SCID was
treated with intravenous gamma globulin once per week. She
received a 5/6 HLA mismatch CBU, with the same RIC regimen
and GVHD prophylaxis as described above. The premedication
used to prevent DMSO toxicity was the same as that in case
one. CBU was infused after thawing and washing. The patient
presented irritability as a side effect during the infusion. She
received 21.48 £ 107/kg of TNC (Table 2) and 12.1 £ 105/kg of
CD34+ cells (Table 3). She engrafted >0.5 £ 109/L neutrophils on
day +13, and >20 £ 109/L platelets on day +15. Thirty-five
months after transplantation the patient was fully engrafted
and free of infections andmedications.
Case 3
A 9-month old Hispanic 4.3 kg male (Table 1) diagnosed with
SCID treated the same as Cases 1 and 2. He was transplanted
with a 5/6 HLA mismatch CBU, using the same RIC regimen,
GVHD and DMSO toxicity prophylaxis, as in the other twoTable 3 – CD34+ cells data.
Case no. CD34+ Before freezing CD34+ Post-
1 13.7 £ 105/kg 8.6 £ 105/kg
2 12.21 £ 105/kg 12.1 £ 105/kg
3 2.68 £ 105/kg 1.7 £ 105/kg
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He received 20.3 £ 107/kg of TNC (Table 2) and 1.7 £ 105/kg of
CD34+ cells (Table 3). He engrafted >0.5 £ 109/L neutrophils
on day +11, and >20 £ 109/L platelets on day +17. Thirty-two
months after transplantation the patient is 95% engrafted
and free of infections andmedications.
In the cases presented above, vital signs were monitored
during hematopoietic cell infusion, without significant
changes, except for heart rate from 120 to 154 beats per min-
ute in case number 2, which was related to irritability of the
patient and was considered within normal limits. Chimerism
analyzed on day +30 after transplantation in each patient was
95%, 100%, and 90%, respectively.Discussion
To preserve hematopoietic progenitor units, it is necessary to
freeze them in liquid nitrogen at storage temperatures rang-
ing from 196° to 150 °Celsius.1 For long-term preservation,
the use of substances such as DMSO is helpful for cryoprotec-
tion and preservation of cell viability.
DMSO is a small amphipathic molecule with a highly polar
domain and two apolar groups, making it soluble in aqueous
and organic media. Due to its vast pharmacokinetic volume
distribution affects multiple organ systems with large spec-
trum toxicities, including blood- brain barrier penetration.1
FDA has approved DMSO since 1978 for intravesical instilla-
tion and for treating musculoskeletal, dermatological, uri-
nary, pulmonary, renal diseases and even cerebral edema.
This cryopreservative additive (CPA) is used as the standard
method, at a 10% concentration, for HSCT in most institu-
tions.1−10
DMSO AEs occur in both, children and adults, although
they are expected to be greater in children due to the amount
of DMSO per kg of weight. Toxicity is related to the amount of
DMSO in the HSCT cryopreserved units and the maximum
dose allowed is 1 g/kg of recipient body weight. DMSO can
cause diverse systemic AEs such as nausea, vomiting, rashes,
massive cardiac arrest, renal failure and neurological compli-
cations.2 These effects may be derived from DMSO-induced
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side effects could be multifactorial.1−4 Ikeda et al. reported
that after infusion of umbilical cord blood units, the most fre-
quent AE is bradycardia, while in cryopreserved bone marrow
units was hypertension.4,5 Central nervous AEs that may be
associated with DMSO are epileptic seizures, stroke, transient
and temporary leukoencephalopathy and global amnesia.6 It
is worth noting that AEs are generated by DMSO, but also pos-
sibly by alloantigens or a large volume per recipient body
weight.5
A study by Y. Okamoto et al. assessed the toxicity observed
after transfusion of cryopreserved and thawed-without wash-
ing PBSC in children aged 1 to 16 years. The patients’ body
weights ranged from 9 to 78 kg. They reported mild AEs in
most pediatric patients after thawing cells from DMSO. The
most common toxicities were hemoglobinuria (74.1%), head-
ache (70.4%), nausea (68.5%) and vomiting (46.3%). Only 15%
of the patients had more severe symptoms such as transient
shock; however, patients recovered promptly and
completely.7 Severe toxicity tends to appear mostly in non-
washed infusions, leaving the washing protocol as essential
element for a successful hematopoietic transplant without
untoward reactions, as in the cases described by Sanchez-
Salinas.2
Although thousands of stem cell units from different sour-
ces are cryopreserved using DMSO and transfused each year,
there have been few reports on the incidence of AEs in chil-
dren weighting less than 5 kg with cryopreserved products.
While Ikeda et al. mentioned gastrointestinal manifestations,
bradycardia, hypertension and allergic reactions in the pedi-
atric population, in our three cases, there were no AEs except
for irritability.3−5 We can only assume that this patient had
abdominal or retrosternal pain, or even nausea, and this was
the reason for the irritability, even though the 3 patients were
premedicated with an antihistamine and ondansetron, in
order to avoid them. However, in our experience (data not
published), in 146 cryopreserved units infused in children and
adults, nausea, vomiting, bradycardia, hypotension and desa-
turation were presented in an adult patient, so that even
adults should be monitored during the infusion of cryopre-
served hematopoietic progenitor cells.
Syme et al. compared a non-washed-cells auto graft group
versus a washed-cells auto graft group8 and found AEs in
both groups. Some symptoms, most of them gastrointestinal,
were more common in the non-washed-cells group. Never-
theless, symptoms such as mucositis, fatigue, facial flushing
and discomfort were similar in both groups. They reported as
well one patient who experienced a grade 1 cardiac AE in the
washed-cell group. This may help to prove that washing the
cells does not exempt patients from presenting AEs.
There are currently some alternatives to reduce patient
exposure to DMSO by a prolonged infusion, DMSO depletion
after thaw-processing, or using alternative CPAs with or with-
out DMSO.1
The current standard post-thaw depletion method, or
Rubinstein’s method9, includes a wash step to remove DMSO,
lysed red cells, and remove stroma. The wash step procedure
was performed in our laboratory with 20% human albumin
(Grifols Biological, Inc. Los Angeles, USA) mixed with Saline
0.9% (Laboratorios PiSA, Mexico City, Mexico) to create a 5%Please cite this article as: C. Mancías-Guerra et al., Dimethyl sulfoxide tox
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Laboratorios PiSA, Mexico City, Mexico). Most institutions
included this method in patients under 20 kg of weight due to
the risk of reaching the recommended maximum dose of
DMSO. Dymethil sulfoxide-depletion has shown a potential
benefit in reducing the risk of events due to DMSO toxicity;
however, when DMSO wash process is made, it might be
responsible for nearly half of the cell loss of the infused unit.
To make the best decision, these two scenarios should be
weighed.10 Worth noting, when DMSO is washed, it does not
completely prevent the occurrence of AEs related to the infu-
sion. This process only minimizes the incidence of AEs, as
anaphylaxis is not dose dependent and in Rubinstein’s
method there is a residual amount of DMSO that remains in
the unit to be infused.
On the other hand, engraftment after UCBT is highly
dependent on the TNC dose per kg of weight. In low weight
patients, DMSO toxicity can be reduced, without cellular
death being a problem, because it is easy to find CBUs to
transplant these small patients. However, we cannot forget
that it is also true that the lower the weight of the patient, the
greater the residual amount of DMSO per kilo of weight,
which may lead to AEs in low-weight patients.
To our knowledge, there are few reports of DMSO adverse
events in children weighting less than 5 kg, possibly because
UCBT in pediatric patients is usually performed with CBU
washed by Rubinstein’s method. This method seems to be
the most convenient technique to process hematopoietic pro-
genitor units, guaranteeing TNC recovery and preserving cell
viability9, at least in pediatric patients.
The patients presented in this report have in common that
the CBUs were washed after thawing. In our experience of 65
non-washed after thawing placental blood allografts (data
not published), only three cases presented DMSO toxicity (3/
66=4.54%). The side effects were acute renal failure, anaphy-
laxis, hemolysis and arrhythmia, all of which resolved. This
supports the hypothesis of Sanchez-Salinas2 regarding the
benefits of washing cells after thawing. Further studies are
required to confirm these findings.Conclusion
DMSO toxicity in UCBT in pediatric patients may be a serious
complication that must be monitored. Using low doses of
DMSO obtained by washing CBUs may be safer than using
non-washing units, with a minimum and transient risk of
toxicity. This could be the best way to transplant children
under 10 kg of body weight. Although washing the CBU can
cause cell loss, in these children, the loss is unlikely to have
an impact at the time of transplantation, since the cell ratio
per kilogram of weight remains high after washing. However,
there is always a risk of serious allergic reactions, even with a
minimum amount of DMSO.Conflicts of interest
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